| DC Field | Value | Language |
|---|
| dc.contributor.author | Lebedeva, A. A. | - |
| dc.contributor.author | Kavun, A. I. | - |
| dc.contributor.author | Belova, E. V. | - |
| dc.contributor.author | Antonova, T. G. | - |
| dc.contributor.author | Semenova, A. B. | - |
| dc.date.accessioned | 2025-04-24T13:10:07Z | - |
| dc.date.available | 2025-04-24T13:10:07Z | - |
| dc.date.issued | 2025 | - |
| dc.identifier.citation | Pathway directed mechanisms of anti-EGFR resistance in colorectal cancer (review) / A.A. Lebedeva, A.I. Kavun, E.V. Belova [et al.] // Научные результаты биомедицинских исследований. - 2025. - Т.11, №1.-С. 5-30. - Doi: 10.18413/2658-6533-2025-11-1-0-1. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/64976 | - |
| dc.description.abstract | In this review, in light of recent findings, we aimed to summarize existing data on the influence of various signaling pathways and their individual components along with nongenomic factors for the optimal patient selection for anti-EGFR MAbs | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | medical genetics | ru |
| dc.subject | colorectal cancer | ru |
| dc.subject | epidermal growth factor receptor | ru |
| dc.subject | anti-EGFR resistance | ru |
| dc.subject | cetuximab | ru |
| dc.subject | panitumumab | ru |
| dc.subject | anti-EGFR monoclonal | ru |
| dc.title | Pathway directed mechanisms of anti-EGFR resistance in colorectal cancer (review) | ru |
| dc.type | Article | ru |
| Appears in Collections: | Т. 11, № 1
|
